Compare AMETEK, Inc. (AME) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? AMETEK, Inc. trades at $231.8 (market cap $53.63B), while Inovio Pharmaceuticals Inc trades at $1.2 (market cap $97.91M). The key difference: AMETEK, Inc. is far larger — about 547.7× Inovio Pharmaceuticals Inc's market cap, and AMETEK, Inc. pays a 0.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AME | INO | |
|---|---|---|
Market Cap | $53.63B | $97.91M |
Sector | Industrials | Health |
52-Week High | $241.94 | $2.87 |
52-Week Low | $176.44 | $1.05 |
Enterprise Value | $55.33B | $68.92M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.
The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
